Phosphodiesterase 4 Inhibitors
"Phosphodiesterase 4 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 4.
| Descriptor ID |
D058988
|
| MeSH Number(s) |
D27.505.519.389.735.374
|
| Concept/Terms |
Phosphodiesterase 4 Inhibitors- Phosphodiesterase 4 Inhibitors
- Inhibitors, Phosphodiesterase 4
- PDE4 Inhibitors
- Inhibitors, PDE4
- Phosphodiesterase Type 4 Inhibitors
- PDE-4 Inhibitors
- Inhibitors, PDE-4
- PDE 4 Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 4 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 4 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 4 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 4 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase 4 Inhibitors" by people in Profiles.
-
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017 09; 50(3).
-
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul; 73(1):37-49.
-
RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects. Br J Pharmacol. 2013 Feb; 168(4):1001-14.
-
Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoA. Inflamm Bowel Dis. 2012 Jun; 18(6):1081-91.